Anti-VEGF pharmacotherapy has revolutionized the treatment of diverse retinal diseases including AMD, diabetic retinopathy, and retinal vascular diseases. Although these agents significantly reduce the risk of vision loss, several challenges remain, including high treatment burden, cost, and suboptimal response or loss of initial gain in vision after long-term therapy.Other challenges include the effect of high treatment burden on patients with comorbidities such as glaucoma.